Mylan Pharma rolls out generic benign prostatic hyperplasia drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

- Advertisement -

Mylan Pharmaceuticals has introduced Alfuzosin Hydrochloride Extended-release Tablets, 10mg.Mylan’s Alfuzosin Hydrochloride Extended-release Tablets, 10mg are generic equivalent to Uroxatral, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Uroxatral belongs to a group of drugs called alpha-adrenergic blockers.Uroxatral relaxes the muscles in the prostate and bladder neck, making it easier to urinate.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Why Pharma’s Workforce Gap Is Now an Operations Problem

When to Bring in Outside Help for FDA Cybersecurity Compliance (and…

Billerud Introduces New Pharmaceutical Packaging Option

AstraZeneca Advances AI Drug Discovery Deal with insitro

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

RABS upgrade for Inibsa, Achieving Annex 1 compliance together

Milestone Leadership in Action: Behaviors That Build Winning Biotech Companies

Beyond the Digital Foundation: How Connected Intelligence Is Redefining Pharma Production

India’s ₹2,333 Crore Weight-Loss Drug Story: Mounjaro, Semaglutide and the Next…

eschbach Launches New Digital Leader Standard Work Capability for Pharma Process…

UCB Reports New EADV Data on Bimekizumab Treatment in HS

CPHI Sustainability Summit Targets Practical Pharma Action

Sterling Expands ADC Manufacturing Capacity and Capabilities

eschbach Launches New Digital Leader Standard Work Capability for Pharma Process…

94th CMEF to Bring Global Medical Device Industry Together in Beijing

Mylan Pharma rolls out generic benign prostatic hyperplasia drug

Why Pharma’s Workforce Gap Is Now an Operations Problem

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Billerud Introduces New Pharmaceutical Packaging Option

Never miss a pharmaceutical headline

Ensuring Patient Safety through Enhanced Opening...

Enhancing Sterile Integrity through Advanced Lid...

Establishing Sterile Reliability through Seal Process...

Enhancing Pharmaceutical Safety through Optimized Product...

Enhancing Moisture Protection through High-Barrier Foil...

Optimizing Pouch Closure Performance through Advanced...

Billerud Introduces New Pharmaceutical Packaging Option

AstraZeneca Advances AI Drug Discovery Deal...

Why Pharma’s Workforce Gap Is Now an Operations Problem

When to Bring in Outside Help for FDA Cybersecurity Compliance (and What to Look For)

Billerud Introduces New Pharmaceutical Packaging Option

AstraZeneca Advances AI Drug Discovery Deal with insitro

About us

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Why Pharma’s Workforce Gap Is Now an Operations Problem

When to Bring in Outside Help for FDA Cybersecurity Compliance (and...